Intrexon Corp. (NYSE:XON) traded up 2.5% on Monday . The stock traded as high as $25.40 and last traded at $25.16, with a volume of 397,861 shares traded. The stock had previously closed at $24.55.

Several equities research analysts recently weighed in on the company. Griffin Securities restated a “buy” rating and set a $65.00 target price on shares of Intrexon Corp. in a research note on Tuesday, June 7th. Zacks Investment Research upgraded Intrexon Corp. from a “hold” rating to a “strong-buy” rating and set a $32.00 target price for the company in a research note on Tuesday, May 3rd. Wunderlich restated a “buy” rating and set a $50.00 target price on shares of Intrexon Corp. in a research note on Thursday, July 7th. Stifel Nicolaus restated a “buy” rating and set a $57.00 target price on shares of Intrexon Corp. in a research note on Wednesday, June 29th. Finally, JMP Securities restated a “buy” rating on shares of Intrexon Corp. in a research note on Sunday. One equities research analyst has rated the stock with a sell rating, four have given a hold rating, five have assigned a buy rating and one has given a strong buy rating to the stock. The company presently has an average rating of “Buy” and an average target price of $49.96.

The company has a 50 day moving average of $26.11 and a 200-day moving average of $29.84. The company’s market capitalization is $3.01 billion.

Intrexon Corp. (NYSE:XON) last announced its quarterly earnings data on Tuesday, May 10th. The company reported ($0.55) earnings per share for the quarter, missing the consensus estimate of ($0.20) by $0.35. The firm had revenue of $43.40 million for the quarter, compared to analysts’ expectations of $46.26 million. The company’s revenue for the quarter was up 28.4% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.25 EPS. On average, equities analysts forecast that Intrexon Corp. will post ($1.32) EPS for the current fiscal year.

In related news, CEO Randal J. Kirk acquired 41,830 shares of the company’s stock in a transaction dated Friday, May 13th. The shares were purchased at an average price of $23.92 per share, for a total transaction of $1,000,573.60. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

Several institutional investors recently made changes to their positions in the stock. Profund Advisors LLC raised its position in shares of Intrexon Corp. by 0.9% in the fourth quarter. Profund Advisors LLC now owns 35,118 shares of the company’s stock valued at $1,059,000 after buying an additional 326 shares in the last quarter. State of Wisconsin Investment Board increased its stake in Intrexon Corp. by 2.5% in the fourth quarter. State of Wisconsin Investment Board now owns 35,410 shares of the company’s stock valued at $1,068,000 after buying an additional 880 shares during the last quarter. Bank of Montreal Can increased its stake in Intrexon Corp. by 16.8% in the fourth quarter. Bank of Montreal Can now owns 40,010 shares of the company’s stock valued at $1,207,000 after buying an additional 5,742 shares during the last quarter. Rhumbline Advisers increased its stake in Intrexon Corp. by 6.7% in the fourth quarter. Rhumbline Advisers now owns 46,016 shares of the company’s stock valued at $1,387,000 after buying an additional 2,890 shares during the last quarter. Finally, State Board of Administration of Florida Retirement System increased its stake in Intrexon Corp. by 15.4% in the fourth quarter. State Board of Administration of Florida Retirement System now owns 50,351 shares of the company’s stock valued at $1,518,000 after buying an additional 6,705 shares during the last quarter.

Intrexon Corporation (Intrexon) forms collaborations to create biologically based products and processes using synthetic biology. The Company designs, builds and regulates gene programs, which are deoxyribonucleic acid (DNA) sequences that consist of genetic components. The Company’s synthetic biology capabilities include the ability to control the amount, location and modification of biological molecules to control the function and output of living cells and optimize for desired results at an industrial scale.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.